Psoriasis is one of the most common chronic inflammatory skin diseases and predominantly affects the skin and joints. 1,2 Various comorbidities and risk factors interact with each other and affect the pathogenesis of psoriasis. 3 Metabolic syndrome is strongly associated with the onset and exacerbation of psoriasis, and patients with psoriasis are at increased risk of cardiovascular disease, which is ascribed not only to metabolic syndrome but also to chronic systemic inflammation. 4 Additionally, patients with psoriasis have an increased risk of cancer. 5 Recently, the concept of psoriatic march has been widely accepted in the pathogenesis of psoriasis. 6 In patients with moderate-to-severe psoriasis, systemic therapies are required to control the disease, and biologics can provide significant

No abstract

Epidermolysis bullosa acquisita is an autoimmune blistering disease in which the type VII collagen of the epidermis basement membrane is the antigen. We encountered a case of epidermolysis bullosa acquisita with initial symptoms on the oral mucosa. The case involved an 82-year-old man referred to our hospital for diagnosis of oral blisters. We diagnosed epidermolysis bullosa acquisita using immunoserology. Symptoms improved after administration of a steroid and colchicine. At eight months after the start of treatment, the patient continued to take prednisolone (10 mg/day) and colchicine (1.0 mg/day) without worsening of oral symptoms that would have impaired quality of life. Extensive blistering in the oral mucosa is highly likely to cause poor pain control and decreased oral intake, and the role of oral hygiene management and symptomatic treatment is very important.